RNF43 and neoplasm: ETC-159 combined with MEK inhibitor Trametinib synergistically inhibits cell cycle progression and in vivo tumor growth of RNF43-mutant PDAC, leading study authors to propose that WNT may temper excessive and potentially deleterious MAPK/ERK signaling in RNF43-mutant PDAC (Zheng et al., 2021).